ArticleCellular oncology (Dordrecht, Netherlands)2011
Gender and ploidy in cancer survival.
Article in Cellular oncology (Dordrecht, Netherlands), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Pooled it
- Assessment of the Type and Degree of Genomic Instability in Gliomas.International journal of molecular sciences · 2026Article
- Life Factors and Melanoma: From the Macroscopic State to the Molecular Mechanism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Ploidy status analysis in small cell lung cancer cells and its use in cytopathological diagnosis.International journal of clinical and experimental pathology · 2025Article
- Inferring allele-specific copy number aberrations and tumor phylogeography from spatially resolved transcriptomics.Nature methods · 2024Article
- Prognostic value and chemotherapy response prediction of a proliferation essential gene signature in colon cancer.Bioscience reports · 2023Article
- Delineating intra-tumoral heterogeneity and tumor evolution in breast cancer using precision-based approaches.Frontiers in genetics · 2023Review
- Classification and Treatment of Diseases in the Age of Genome Medicine Based on Pathway Pathology.International journal of molecular sciences · 2021Review
- IMP3 protein is an independent prognostic factor of clinical stage II rectal cancer.Scientific reports · 2021Article
- Single-cell analysis of copy-number alterations in serous ovarian cancer reveals substantial heterogeneity in both low- and high-grade tumors.Cell cycle (Georgetown, Tex.) · 2020Article
- Chromosome Abnormalities: New Insights into Their Clinical Significance in Cancer.Molecular therapy oncolytics · 2020Review
- Hierarchical discovery of large-scale and focal copy number alterations in low-coverage cancer genomes.BMC bioinformatics · 2020Article
- Genotypic and Phenotypic Variables Affect Meiotic Cell Cycle Progression, Tumor Ploidy, and Cancer-Associated Mortality in aJournal of oncology · 2019Article
- The Role of Tumor Microenvironment in Genomic Instability of Malignant Tumors.Frontiers in genetics · 2019Review
- Combinational chromosomal aneuploidies and HPV status for prediction of head and neck squamous cell carcinoma prognosis in biopsies and cytological preparations.Journal of cancer research and clinical oncology · 2018Article
- Aneuploidy: a common and early evidence-based biomarker for carcinogens and reproductive toxicants.Environmental health : a global access science source · 2016Review
- Disentangling the aneuploidy and senescence paradoxes: a study of triploid breast cancers non-responsive to neoadjuvant therapy.Histochemistry and cell biology · 2016Article
- Will we cure cancer by sequencing thousands of genomes?Molecular cytogenetics · 2013Article
- A new whole genome amplification method for studying clonal evolution patterns in malignant colorectal polyps.Genes, chromosomes & cancer · 2012Article
- Thoracic neoplasms at the Jena reference center for soft tissue tumors.Journal of cancer research and clinical oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFemales carry a better prognosis than men for many cancer types. We hypothesized that chromosomal changes, in particular numerical alterations of the sex chromosomes or the presence of near-triploidy may contribute to these gender differences.
methodsTo characterize the influence of gender a literature search was performed for survival data of 27 tumor types. All entities were categorized by the strength of evidence for differences in survival between females and males. To test our hypothesis the Mitelman database of chromosomal alterations was evaluated for the major tumor types occurring in both women and men. Numerical gonosome alterations were documented and mean chromosome numbers were converted into histograms to provide insight into the ploidy level of 37 cancer types.
resultsIn general, a survival advantage of women could be shown for most, but not all cancer types. In addition, 36.859 karyograms were analyzed. Numerical gonosome alterations were more frequent in males than females indicating a potential link with gender differences in survival. Neartriploidy was a common phenomenon in many cancer types suggesting that it represents a metastable condition of the cancer genome. It was not related to gender differences in survival. However, the extent of triploidy and aneuploidy was associated with poor prognosis in carcinomas. There was no single case in the Mitelman database with normal chromosome number (n = 46) that did not carry at least one structural or numerical aberration.
conclusionsOur study highlights the importance of chromosomal changes in tumor formation and progression. In addition, it suggests potential associations with gender specific differences in survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.